Home
Science and IP
Investors
Our Team
Events
News Releases
Contact
NASDAQ: CMND
FWB: CWY0
News Releases
Below are the latest News Releases for Clearmind Medicine Inc.
17
November
2023
Clearmind Medicine Announces Receipt of Nasdaq Delisting Notice and Plan for Immediate Recompliance
Read More
15
November
2023
Clearmind Medicine Announces Shareholders Meeting Results
Read More
5
October
2023
Clearmind Medicine to Present at the 8th Annual Dawson James Conference on October 12th
Read More
28
September
2023
Clearmind Medicine to Present at the LD Micro Main Event XVI Investor Conference on October 4th
Read More
18
September
2023
Clearmind Medicine Closes US$2.25 Million Public Offering
Read More
6
September
2023
Clearmind Medicine Announces Clinical Research Collaboration with Johns Hopkins University to Evaluate CMND-100 for AUD
Read More
14
August
2023
Clearmind Medicine Announces Collaboration with CTS Ltd., a Leading Pharmaceutical and Consumer Products Company
Read More
1
August
2023
Clearmind Medicine Files Patent Application with USPTO for the Treatment of Dyskinesia; Further Strengthens its Already Robust IP
Read More
11
July
2023
Dr. Fatima Cody Stanford Joins Clearmind Medicine's Scientific Advisory Board
Read More
16
June
2023
Clearmind Medicine and SciSparc to Conduct Study Evaluating Combination Treatment for Obesity and Metabolic Syndrome
Read More
22
May
2023
Clearmind Medicine Announces First US Site for its Phase I/IIa Clinical Trial Evaluating CMND-100 in Patients with Alcohol Use Dis
Read More
17
May
2023
Clearmind Medicine to Host Virtual Investor Conference on Psychedelics for Obesity
Read More
12
May
2023
Clearmind Medicine Announces IRB Approval to Conduct Clinical Trial on Alcohol Use Disorder
Read More
8
May
2023
Clearmind Medicine Strengthens Scientific Advisory Board with Appointment of Prof. Joseph Tam
Read More
2
May
2023
Clearmind Medicine Announces Clinical Supply Agreement for its Upcoming Clinical Trial
Read More
Previous
Next
